New Enhanced OMIDRIAssure® Patient Access Programs

Learn more

Real-world evidence

OMIDRIA provides an improved patient experience

OMIDRIA significantly improved postoperative day 1 visual acuity across a wide age range1

Improved uncorrected visual acuity on day after surgery was greater for age ranges 62-68, 69-75, 76-92 (OMIDRIA vs Epinephrine)

Of the 641 eyes of 389 patients who underwent cataract surgery, 260 eyes were administered phenylephrine 1.0%/ketorolac 0.3% and 381 eyes received epinephrine in the irrigation solution intraoperatively.1

Immediate improvement in postoperative visual acuity may be attributed to the anti-inflammatory properties of OMIDRIA.1

Single-center, retrospective case review (N=641)1

A single-center, retrospective case review of patients undergoing cataract surgery who received OMIDRIA or epinephrine

All patients received a topical NSAID regimen for 3 days before surgery and topical tropicamide 1.0%, cyclopentolate 1.0%, and phenylephrine 2.5% on the day of surgery.1

OMIDRIA reduces pain during and after surgery

  • The ketorolac component of intracameral OMIDRIA provides higher concentrations compared to topical drops2,3

  • Fewer drops are needed for cataract surgery, so there is a less demanding routine for you, your staff, and your patients2

  • OMIDRIA is easy to integrate into your surgical routine4

During surgery there was a 50% reduction in VAS pain scores with OMIDRIA vs epinephrine. After surgery patients are 50% more likely to be pain-free up to 12 hours after surgery.

Prospective, single-masked, comparative study (N=60)5

In a prospective, single-masked, comparative study, cataract surgeries were performed by a single surgeon

All patients received preoperative topical lidocaine gel for anesthesia, administered 2-3 times 15 minutes before surgery.5
At the start of the surgery, all patients received 0.5 mL of intracameral preservative-free lidocaine 1%.5

Prospective, randomized, clinical trials (N=821)6

In a prospective, randomized study, patients with cataract surgery were enrolled in 2 clinical trials

Preoperative treatments were standardized for all patients and included moxifloxacin 0.5% (Vigamox) treatment for at least 3 days before surgery, mydriatic treatment with topical phenylephrine HCl 2.5% plus tropicamide 1.0% three times in the 30 minutes before surgery, and lidocaine or tetracaine for local anesthesia on the day of surgery.6

REFERENCES: 1. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Clin Ophthalmol. 2018;12:21-28. 2. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872. 3. Donnenfeld ED, Whitaker JS, Jackson MA, Wittpenn J. Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. J Cataract Refract Surg. 2017;43(5):597-605. 4. OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. 2023. 5. Donnenfeld ED, Shojaei RD. Effect of intracameral phenylephrine and ketorolac 1.0%/0.3% on intraoperative pain and opioid use during cataract surgery. Clin Ophthalmol. 2019;13:2143-2150. 6. Hovanesian JA, Sheppard JD, Trattler WB, et al. Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: integrated results from 2 pivotal phase 3 studies. J Cataract Refract Surg. 2015;41:2060-2068.